The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1496
Drugs for Multiple Sclerosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease.1 Treatment usually includes disease-modifying drugs, various other drugs for managing symptoms such as fatigue, depression, and pain, and corticosteroids for acute exacerbations.

INJECTABLE AGENTS — Interferons – Interferon beta was the first disease-modifying drug approved for treatment of MS. Interferons have several immune-modulating and anti-inflammatory effects. They can reduce clinical relapse rates by 30-35% and decrease the number of new T2 or gadolinium-enhancing brain lesions seen on MRI. Whether these effects delay or prevent long-term disability is unclear.2,3 Interferons frequently cause injection-site reactions and a flu-like syndrome.4 Pegylated interferon beta-1a (Plegridy) injected ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Multiple Sclerosis
Article code: 1496a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian